{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:04:55Z","timestamp":1789434295105,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer patients have an increased risk for cardiovascular diseases (CVDs). Conflicting information exists regarding whether cancer treatment with immune checkpoint inhibitors (ICIs) itself increases the risk for CVDs. We therefore assessed the incidence of major adverse cardiovascular events (MACE) in cancer patients treated with versus without ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred fifty-eight and 163 cancer patients, treated with and without ICIs respectively, were compared. The primary endpoint was the incidence of MACE, defined as acute coronary syndrome, ischemic stroke, transient ischemic attack, new or worsening coronary artery disease or peripheral arterial occlusive disease, or cardiovascular death. We used Cox proportional hazard models and competing risk models (death), adjusted for age, sex and comorbidities (Charlson Comorbidity index, CCI) to investigate the cause-specific association between ICI-treatment and MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median follow-up of 30.6\u00a0months, 37 MACE occurred. The overall incidence of MACE was 14.0% in patients with and 9.3% in patients without ICI-treatment. In the multivariate analysis CCI was significantly associated with MACE (HR 1.19, 95% CI [1.03, 1.37]), whereas no association was found for ICI-treatment (HR 1.12, 95% CI [0.56, 2.22]). Competing risk analysis showed no treatment associations. CCI was associated with non-cardiovascular mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We did not observe statistical evidence of an association between ICI treatment and MACE. There is evidence that a higher comorbidity burden is associated with MACE. Comorbidities are clearly associated with non-cardiovascular mortality in cancer patients. Further prospective studies are required to investigate whether treating comorbidities and optimizing cardiovascular risk factors result in improved outcomes among cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16410-7","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:12Z","timestamp":1782712692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between comorbidities and major adverse cardiovascular events in patients undergoing immune checkpoint blockade"],"prefix":"10.1186","volume":"26","author":[{"given":"Eveline","family":"Daetwyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u00efse","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Aeschlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Rommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kasenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-4631","authenticated-orcid":false,"given":"Gabriela M.","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"16410_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","volume":"395","author":"GR Dagenais","year":"2020","unstructured":"Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395:785\u201394.","journal-title":"Lancet"},{"key":"16410_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jaccao.2022.03.004","volume":"4","author":"BNM Luca","year":"2022","unstructured":"Luca BNM, Welch CA, Sweeting M, et al. Prevalence of cardiovascular disease in patients with potentially curable malignancies. JACC CardioOncol. 2022;4:238\u201353.","journal-title":"JACC CardioOncol"},{"key":"16410_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"16410_CR4","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"16410_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1741-7015-11-117","volume":"11","author":"J Frosteg\u00e5rd","year":"2013","unstructured":"Frosteg\u00e5rd J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117.","journal-title":"BMC Med"},{"key":"16410_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-019-0796-0","volume":"21","author":"L Vincent","year":"2019","unstructured":"Vincent L, Leedy D, Masri SC, Cheng RK. Cardiovascular disease and cancer: is there increasing overlap? Curr Oncol Rep. 2019;21:47.","journal-title":"Curr Oncol Rep"},{"key":"16410_CR7","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140:e596\u2013646.","journal-title":"Circulation"},{"key":"16410_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"16410_CR9","doi-asserted-by":"publisher","first-page":"959285","DOI":"10.3389\/fcvm.2022.959285","volume":"9","author":"AV Poznyak","year":"2022","unstructured":"Poznyak AV, Sadykhov NK, Kartuesov AG, et al. Hypertension as a risk factor for atherosclerosis: cardiovascular risk assessment. Front Cardiovasc Med. 2022;9:959285.","journal-title":"Front Cardiovasc Med"},{"key":"16410_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"16410_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12890-017-0452-0","volume":"17","author":"L Zhao","year":"2017","unstructured":"Zhao L, Leung LH, Wang J, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med. 2017;17:112.","journal-title":"BMC Pulm Med"},{"key":"16410_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1183\/09031936.05.00146004","volume":"26","author":"D Moro-Sibilot","year":"2005","unstructured":"Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J. 2005;26:480\u20136.","journal-title":"Eur Respir J"},{"key":"16410_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1010-7940(02)00721-2","volume":"23","author":"\u00d6 Birim","year":"2003","unstructured":"Birim \u00d6, Maat APWM, Kappetein AP, van Meerbeeck JP, Damhuis RAM, Bogers AJJC. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;23:30\u20134.","journal-title":"Eur J Cardiothorac Surg"},{"key":"16410_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.athoracsur.2011.12.092","volume":"94","author":"FG Fernandez","year":"2012","unstructured":"Fernandez FG, Crabtree TD, Liu J, Meyers BF. Sublobar resection versus definitive radiation in patients with stage IA non-small cell lung cancer. Ann Thorac Surg. 2012;94:354\u201360; discussion 360-1.","journal-title":"Ann Thorac Surg."},{"key":"16410_CR15","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"16410_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987\u201398.","journal-title":"N Engl J Med"},{"key":"16410_CR17","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.jacc.2019.03.500","volume":"73","author":"KM Atkins","year":"2019","unstructured":"Atkins KM, Rawal B, Chaunzwa TL, et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol. 2019;73:2976\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"16410_CR18","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.","journal-title":"JAMA Netw Open"},{"key":"16410_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"16410_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"16410_CR21","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"16410_CR22","doi-asserted-by":"crossref","unstructured":"Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8.(2):e001511.","DOI":"10.1136\/jitc-2020-001511"},{"key":"16410_CR23","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40:3430\u20138.","journal-title":"J Clin Oncol"},{"key":"16410_CR24","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299\u2013311.","journal-title":"Circulation"},{"key":"16410_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","volume":"120","author":"J Bar","year":"2019","unstructured":"Bar J, Markel G, Gottfried T, et al. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019;120:122\u201331.","journal-title":"Eur J Cancer"},{"key":"16410_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jaccao.2022.09.003","volume":"4","author":"L Kondapalli","year":"2022","unstructured":"Kondapalli L, Hsia J, Miller R, Flaig TW, Bonaca MP. Burden of cardiovascular disease in immune checkpoint inhibitor-treated patients. JACC CardioOncol. 2022;4:649\u201356.","journal-title":"JACC CardioOncol"},{"key":"16410_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","volume":"196","author":"C Solinas","year":"2020","unstructured":"Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review. Thromb Res. 2020;196:444\u201353.","journal-title":"Thromb Res"},{"key":"16410_CR28","first-page":"19","volume":"7","author":"JC Lal","year":"2021","unstructured":"Lal JC, Brown SA, Collier P, Cheng F. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. Cardiooncology. 2021;7:19.","journal-title":"Cardiooncology"},{"key":"16410_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol. 2019;1:182\u201392.","journal-title":"JACC CardioOncol"},{"key":"16410_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/cvr\/cvx248","volume":"114","author":"PJH Kusters","year":"2018","unstructured":"Kusters PJH, Lutgens E, Seijkens TTP. Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovasc Res. 2018;114:368\u201377.","journal-title":"Cardiovasc Res"},{"key":"16410_CR31","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1111\/bph.13802","volume":"174","author":"AC Foks","year":"2017","unstructured":"Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br J Pharmacol. 2017;174:3940\u201355.","journal-title":"Br J Pharmacol"},{"key":"16410_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/jjco\/hyac041","volume":"52","author":"K Tajiri","year":"2022","unstructured":"Tajiri K, Sekine I. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients. Jpn J Clin Oncol. 2022;52:659\u201364.","journal-title":"Jpn J Clin Oncol"},{"key":"16410_CR33","doi-asserted-by":"publisher","first-page":"962596","DOI":"10.3389\/fphar.2022.962596","volume":"13","author":"L Gan","year":"2022","unstructured":"Gan L, Liu D, Ma Y, et al. Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges. Front Pharmacol. 2022;13:962596.","journal-title":"Front Pharmacol"},{"key":"16410_CR34","unstructured":"Anon. About \u2013 REDCap. https:\/\/projectredcap.org\/about\/. Accessed 24 Mar 2024."},{"key":"16410_CR35","unstructured":"Anon. NHIS - adult alcohol use - glossary. 2019. https:\/\/www.cdc.gov\/nchs\/nhis\/alcohol\/alcohol_glossary.htm. Accessed 27 Jan 2024."},{"key":"16410_CR36","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"16410_CR37","unstructured":"Anon. The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 24 Oct 2023."},{"key":"16410_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/978-1-4612-4380-9_6","volume-title":"Breakthroughs in statistics: methodology and distribution","author":"RA Fisher","year":"1992","unstructured":"Fisher RA. Statistical methods for research workers. In: Kotz S, Johnson NL, editors. Breakthroughs in statistics: methodology and distribution. New York: Springer New York; 1992. p. 66\u201370."},{"key":"16410_CR39","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s44161-022-00131-8","volume":"1","author":"DV Zhernakova","year":"2022","unstructured":"Zhernakova DV, Sinha T, Andreu-S\u00e1nchez S, et al. Age-dependent sex differences in cardiometabolic risk factors. Nat Cardiovasc Res. 2022;1:844\u201354.","journal-title":"Nat Cardiovasc Res"},{"key":"16410_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcdd6020019","volume":"6","author":"JL Rodgers","year":"2019","unstructured":"Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6:19.","journal-title":"J Cardiovasc Dev Dis"},{"key":"16410_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cger.2009.07.007","volume":"25","author":"A Yazdanyar","year":"2009","unstructured":"Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25:563\u201377, vii.","journal-title":"Clin Geriatr Med"},{"key":"16410_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/CIRCRESAHA.111.246876","volume":"110","author":"BJ North","year":"2012","unstructured":"North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110:1097\u2013108.","journal-title":"Circ Res"},{"key":"16410_CR43","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.2018.36.15_suppl.3009","volume":"36","author":"L Amiri-Kordestani","year":"2018","unstructured":"Amiri-Kordestani L, Moslehi J, Cheng J, et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and Drug Administration pooled analysis. J Clin Oncol. 2018;36:3009\u20133009.","journal-title":"J Clin Oncol"},{"key":"16410_CR44","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"16410_CR45","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","volume":"142","author":"R Calabretta","year":"2020","unstructured":"Calabretta R, Hoeller C, Pichler V, et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation. 2020;142:2396\u20138.","journal-title":"Circulation"},{"key":"16410_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels K, van Leent MMT, Boutros C, et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol. 2020;2:599\u2013610.","journal-title":"JACC CardioOncol"},{"key":"16410_CR47","doi-asserted-by":"publisher","first-page":"18933","DOI":"10.1038\/s41598-021-98026-4","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim S, Park J, Kwon JH, et al. The Charlson Comorbidity Index is associated with risk of 30-day mortality in patients with myocardial injury after non-cardiac surgery. Sci Rep. 2021;11:18933.","journal-title":"Sci Rep"},{"key":"16410_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195\u2013211.","journal-title":"Prim Care"},{"key":"16410_CR49","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","volume":"322","author":"J Pekkanen","year":"1990","unstructured":"Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700\u20137.","journal-title":"N Engl J Med"},{"key":"16410_CR50","doi-asserted-by":"crossref","unstructured":"Anon. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100:1132\u20131133.","DOI":"10.1161\/01.CIR.100.10.1132"},{"key":"16410_CR51","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/archinte.162.16.1867","volume":"162","author":"PWF Wilson","year":"2002","unstructured":"Wilson PWF, D\u2019Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867\u201372.","journal-title":"Arch Intern Med"},{"key":"16410_CR52","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"16410_CR53","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","volume":"144","author":"Y Yeghiazarians","year":"2021","unstructured":"Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144:e56\u201367.","journal-title":"Circulation"},{"key":"16410_CR54","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372.","journal-title":"Circulation"},{"key":"16410_CR55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrneph.2017.51","volume":"13","author":"A Gister\u00e5","year":"2017","unstructured":"Gister\u00e5 A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13:368\u201380.","journal-title":"Nat Rev Nephrol"},{"key":"16410_CR56","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71:2100\u201311.","journal-title":"Arthritis Rheumatol"},{"key":"16410_CR57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234\u201340.","journal-title":"JAMA Oncol"},{"key":"16410_CR58","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"16410_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","volume":"4","author":"DI Paterson","year":"2022","unstructured":"Paterson DI, Wiebe N, Cheung WY, et al. Incident cardiovascular disease among adults with cancer. JACC CardioOncol. 2022;4:85\u201394.","journal-title":"JACC CardioOncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16410-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16410-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16410-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:02Z","timestamp":1789434122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16410-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16410"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16410-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Northwestern and Central Switzerland (2023\u201300832) and conducted in accordance with the principles of the Declaration of Helsinki. All participants signed the general research consent, which is a type of informed consent that allows the use of health-related data for future unspecified research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ED, AJ, NAe, NR: none.BK received grants from Dayton Therapeutics, PharmaAnd as well as payments\/honoraria for lectures, presentations\/educational events and manuscript writing from Incyte and Roche, all outside of this work and paid to the institution.AZ received consulting\/advisor fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Hoffmann\u2013La Roche, NBE Therapeutics, Engimmune, and maintains further non-commercial research agreements with Roche, Vectorbiopharma, T3 Pharma, AstraZeneca and Bright Peak Therapeutics, all outside of this work and paid to the institution.GMK received speaker and consulting\/advisor fees from Janssen and consulting\/advisor fees from PAGE Therapeutics, all outside of this work and paid to the institution.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1094"}}